Figure 2From: Evaluating the cost effectiveness of donepezil in the treatment of Alzheimer's disease in Germany using discrete event simulation Cost-effectiveness scatter plot for patients with 26 ≥ MMSE ≥ 10: donepezil versus no treatment. Distribution of replications: 0.8% in upper right quadrant (donepezil leads to incremental costs and higher QALYs), 99.2% in lower right quadrant (donepezil dominant, leading to lower costs and higher QALYs).Back to article page